© Frontline Medical Communications 2018-2021. Reprinted with permission, all rights reserved.
Converge Coverage
Uptake of new heart failure drugs slow despite guidelines
EXPERT ANALYSIS FROM THE CARDIOVASCULAR CONFERENCE AT SNOWMASS
Related Articles
Higher Rates of Major Hemorrhage with Rivaroxaban and Warfarin
April 5, 2017
Clinical question: How effective and safe are apixaban versus rivaroxaban versus warfarin in patients with cirrhosis and nonvalvular atrial fibrillation (AF)? Background: Apixaban, rivaroxaban, and...
Detectable MNPs in Carotid Artery Plaques Are Associated with a Higher Risk of Myocardial Infarction, Stroke, or Death
April 5, 2017
Clinical question: Do patients with carotid artery plaque containing detectable microplastics and nanoplastics (MNPs) have a higher risk of myocardial infarction, stroke, or death? Background:...
Improving HF Outcomes in Obesity and Type 2 Diabetes: The Role of Semaglutide
April 5, 2017
Clinical question: Does semaglutide improve heart failure (HF) symptoms in patients with obesity-related HF and type 2 diabetes? Background: Obesity-related HF and type 2 diabetes are prevalent...
Acute Cardiac Events are Common Among Adults 50 Years or Older Hospitalized with RSV and Associated with Severe Disease
April 5, 2017
Clinical question: How common are acute cardiac events among hospitalized older adults (50 years or older) with respiratory syncytial virus (RSV) infection and what are the associated risk...